Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing Pharmaceutical Investing
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs Pharmaceutical Investing
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® Life Science Investing
Potent Ventures Inc. Announces Commencement of Trading of Common Shares Under the Symbol "GUMY" and Formal Change of Name Biotech Investing
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib in Patients with Axial Spondyloarthritis at EULAR 2022 Pharmaceutical Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
